Gene Mechanism Reveals Gender Disparity in Lung Cancer Outcomes
TL;DR
Women with lung cancer may have poorer outcomes due to pregnancy-specific genes, creating opportunities for immune therapy companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI).
Study at Memorial Sloan Kettering (MSK) Cancer Center reveals lung cancer hijacks genes linked to fetal growth to evade the immune system, impacting patient outcomes.
Understanding how genes affect immune response in lung cancer can lead to the development of effective immune therapies, potentially improving outcomes for patients in the future.
Research suggests that genes involved in fetal growth can play a role in lung cancer progression, offering new insights into cancer development and treatment strategies.
Found this article helpful?
Share it with your network and spread the knowledge!
Researchers at Memorial Sloan Kettering Cancer Center have uncovered a critical mechanism explaining why women with lung cancer experience worse clinical outcomes, linking the phenomenon to genes typically associated with pregnancy.
The study revealed that lung cancer can co-opt genes normally responsible for fetal growth, enabling the disease to circumvent the patient's immune system defenses. By activating these pregnancy-specific genes, cancer cells create an environment that impedes the body's natural immune response.
This groundbreaking research provides crucial insights into the complex interactions between genetic mechanisms and cancer progression. For women diagnosed with lung cancer, understanding these genetic pathways could potentially lead to more targeted and personalized treatment approaches.
The findings highlight the intricate ways cancer adapts and manipulates cellular processes, suggesting that gender-specific genetic variations might play a significant role in disease progression and patient outcomes.
As immunotherapy continues to evolve, this research offers a promising avenue for developing more effective strategies to combat lung cancer, particularly in female patients. By understanding how these specific genes function, researchers may be able to develop interventions that neutralize the cancer's ability to evade immune detection.
Curated from InvestorBrandNetwork (IBN)
